Farrell AT - Search Results

1

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis.

Kasamon YL, Ko CW, Subramaniam S, Ma L, Yang Y, Nie L, Shord S, Przepiorka D, Farrell AT, McKee AE, Pazdur R. Kasamon YL, et al. Among authors: farrell at. Oncologist. 2018 Dec;23(12):1511-1519. doi: 10.1634/theoncologist.2018-0222. Epub 2018 Aug 16. Oncologist. 2018. PMID: 30115735 Free PMC article.

2

Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

Cohen MH, Farrell A, Justice R, Pazdur R. Cohen MH, et al. Oncologist. 2009 Feb;14(2):174-80. doi: 10.1634/theoncologist.2008-0255. Epub 2009 Feb 4. Oncologist. 2009. PMID: 19193781 Free article. Clinical Trial.

3

FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.

Deisseroth A, Ko CW, Nie L, Zirkelbach JF, Zhao L, Bullock J, Mehrotra N, Del Valle P, Saber H, Sheth C, Gehrke B, Justice R, Farrell A, Pazdur R. Deisseroth A, et al. Clin Cancer Res. 2015 Mar 1;21(5):950-4. doi: 10.1158/1078-0432.CCR-14-1678. Epub 2015 Jan 19. Clin Cancer Res. 2015. PMID: 25601959 Review.

4

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.

Oneal PA, Kwitkowski V, Luo L, Shen YL, Subramaniam S, Shord S, Goldberg KB, McKee AE, Kaminskas E, Farrell A, Pazdur R. Oneal PA, et al. Oncologist. 2018 Dec;23(12):1520-1524. doi: 10.1634/theoncologist.2018-0295. Epub 2018 Aug 17. Oncologist. 2018. PMID: 30120160 Free PMC article.

5

U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.

Pulte ED, Wroblewski T, Bloomquist E, Tang S, Farrell A, Deisseroth A, McKee AE, Pazdur R. Pulte ED, et al. Oncologist. 2019 May;24(5):e188-e195. doi: 10.1634/theoncologist.2018-0759. Epub 2019 Apr 24. Oncologist. 2019. PMID: 31019020 Free PMC article.

6

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Kane RC, Bross PF, Farrell AT, Pazdur R. Kane RC, et al. Among authors: farrell at. Oncologist. 2003;8(6):508-13. doi: 10.1634/theoncologist.8-6-508. Oncologist. 2003. PMID: 14657528 Free article. Review.

7

FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.

Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R. Kaminskas E, et al. Among authors: farrell at. Oncologist. 2005 Mar;10(3):176-82. doi: 10.1634/theoncologist.10-3-176. Oncologist. 2005. PMID: 15793220 Free article. Review.

8

Sorafenib for the treatment of unresectable hepatocellular carcinoma.

Kane RC, Farrell AT, Madabushi R, Booth B, Chattopadhyay S, Sridhara R, Justice R, Pazdur R. Kane RC, et al. Among authors: farrell at. Oncologist. 2009 Jan;14(1):95-100. doi: 10.1634/theoncologist.2008-0185. Epub 2009 Jan 14. Oncologist. 2009. PMID: 19144678 Free article. Review.

9

The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.

McKee AE, Farrell AT, Pazdur R, Woodcock J. McKee AE, et al. Among authors: farrell at. Oncologist. 2010;15 Suppl 1:13-8. doi: 10.1634/theoncologist.2010-S1-13. Oncologist. 2010. PMID: 20237212 Free article.

10

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R. Kwitkowski VE, et al. Among authors: farrell at. Oncologist. 2010;15(4):428-35. doi: 10.1634/theoncologist.2009-0178. Epub 2010 Mar 23. Oncologist. 2010. PMID: 20332142 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page